anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Glycopyrrolate
Trial phase: Phase 2
ATC code: A03AB02
SMILES: C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: glycopyrrolate Topical Wipes, 4.0%
Eligibility criteria:
Inclusion Criteria:

Male or female, 18 years of age or older.
Primary, axillary hyperhidrosis of at least 6 months duration.
A Hyperhidrosis Disease Severity Score (HDSS) of 3or 4.
A gravimetric measurement of sweat production of at least 50 mg over 5 minutes in each axilla (total of 100 mg) while at rest at room temperature.
Male or non-pregnant, non-lactating females.

Exclusion Criteria:

Prior surgical procedure for hyperhidrosis.
Any prior treatment with an axillary anti-hyperhidrosis medical device (approved or investigational)
Prior treatment with botulinum toxin for axillary hyperhidrosis within 1 year.
Treatment with cholinergic, serotonergic antagonists, and dopamine partial agonists thought to relieve antidepressant-induced hyperhidrosis. Treatment with psychotherapeutic medications for less than 4 months prior to study enrollment. - Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine), or beta-blockers within 4 weeks prior to enrollment.
Prior axillary treatment with axillary iontophoresis within 4 weeks.
Axillary use of nonprescription or prescription antiperspirants within 2 weeks of study enrollment.
Known history of a condition that may cause secondary hyperhidrosis.
Known history of Sjögren's syndrome or Sicca syndrome.
Abnormal findings on screening ECG deemed clinically significant by the Investigator.
Intervention: Mitomycin
Trial phase: Phase 2
ATC code: L01DC03
SMILES: [H][C@]12N[C@@]1([H])CN1C3=C(C(=O)C(N)=C(C)C3=O)[C@@H](COC(N)=O)[C@]12OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 45
Group description: Randomization stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.

Irrigation placement

Mitomycin-C
Eligibility criteria:
Inclusion Criteria:

Men or women aged 18 years and older at screening.
Diagnosis of chronic angle-closure glaucoma or open-angle glaucoma, phakic or pseudophakic, with visual field or optic disc changes characteristic of glaucoma.
Suitable candidate for trabeculectomy with Ex-PRESS glaucoma filtration device with MMC in the superonasal quadrant in the study eye which the physician deems as medically necessary.
Capable and willing to provide consent

Exclusion Criteria:

Unable or unwilling to provide consent
Any previous ocular surgeries in the study eye preventing placement of the trabeculectomy with Ex-PRESS glaucoma filtration device with mitomycin-C in the superonasal quadrant
Any previous glaucoma drainage devices in the study eye
Any abnormality other than glaucoma in the study eye that could affect applanation tonometry.
Presence or history of any abnormality or disorder that could interfere with the study procedure or prevent the successful completion of the study.
Presence or history of uveitis within 10 years or any other ocular infection or inflammation within 14 days before day 1.
Any significant unstable cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.

Known Pregnancy or Breastfeeding

Physical and Laboratory Findings

Conjunctival scarring precluding a superonasal implantation location.
Vitreous in the anterior chamber.
Abnormality preventing reliable applanation tonometry in the study eye.
Intervention: Erythromycin
Trial phase: Not Applicable
ATC code: D10AF02 | D10AF52 | J01FA01 | S01AA17
SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure

Erythromycin
Eligibility criteria:
Inclusion Criteria:

Adult patients (18-80)
who are admitted to the ICU for hematemesis, or coffee ground emesis

Exclusion Criteria:

Patients younger than 18 yrs old or older than 80 yrs
Patients who refuse to consent to be in our study
Pregnant patients
Prior use of prokinetics in the last 48 hours
History of cardiac arrhythmia
Allergy to erythromycin or metoclopromide

Patients with QT prolongation (query 7)

-
Intervention: Triheptanoin
Trial phase: Phase 1
ATC code: A16AX17
SMILES: CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC
Sex: All
Age groups: Child | Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 14
Group description: Triheptanoin (C7 oil, liquid) dosed at 1 g/kg body weight divided and administered 4 times per day via mouth or g-tube for 3 months.

Triheptanoin: Triheptanoin is a 7-carbon medium chain triglyceride
Eligibility criteria:
Inclusion Criteria:

Male or Female
Ages 1 month to <21 years of age
Diagnosed with glucose transporter type I deficiency.
Age matched (within 1 year) controls not diagnosed with G1D.

Exclusion Criteria:

All subjects carrying body metal implants incompatible with the exposure to a magnetic field
Subjects unable to tolerate the MRI and MRS procedures due to anxiety
Subjects receiving oxygen supplementation or those confined to a bed or stretcher
Subjects currently receiving a ketogenic diet, due to a high risk of seizure recurrence while transitioning off ketosis.
Patients behaviorally unable to hold still for imaging procedures (rather than limited by seizure activity) will be excluded.
Intervention: Parsaclisib
Trial phase: Phase 1 | Phase 2
ATC code: L01EM05
SMILES: CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Participants self-administered parsaclisib 5 milligrams (mg) as an oral tablet once a day (QD) in 21-day treatment cycles.
Eligibility criteria:
Inclusion Criteria:

Aged 18 years or older, with lymphoid malignancies of B-cell origin including:

Indolent / aggressive B-cell non-Hodgkin's lymphoma (NHL)

EXCLUDING: Burkitt's lymphoma and precursor B lymphoblastic leukemia/lymphoma
INCLUDING: any non-Hodgkin's B cell malignancy such as chronic lymphocytic leukemia (CLL) and rare non-Hodgkin's B- cell subtypes such as hairy cell leukemia, Waldenström macroglobulinemia (WM), mantle cell leukemia (MCL), and transformed NHL histologies
Hodgkin's lymphoma (HL)
Life expectancy of 12 weeks or longer
Subject must have received ≥ 1 prior treatment regimen(s)
The subject must not be a candidate for potentially curative therapy including hematopoietic stem cell transplantation, except where one of the standard therapy regimen combinations may be used prior to transplantation per standard medical practice

Exclusion Criteria:

Has history of brain metastasis, spinal cord compression (unless treated, asymptomatic, and stable on most recent imaging and enrolling in expansion cohort), or lymphoma involving the central nervous system (CNS)
Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3 (≥ 2 during dose escalation)
Received allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or currently receiving immunosuppressive therapy following allogeneic transplant
Received autologous hematopoietic stem cell transplant within the last 3 months
Inadequate marrow reserve assessed by hematologic laboratory parameters
Inadequate renal or liver function
Known HIV infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or at risk for HBV reactivation
Intervention: Parsaclisib
Trial phase: Phase 1 | Phase 2
ATC code: L01EM05
SMILES: CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Participants self-administered parsaclisib 15 mg as oral tablets QD in 21-day treatment cycles.
Eligibility criteria:
Inclusion Criteria:

Aged 18 years or older, with lymphoid malignancies of B-cell origin including:

Indolent / aggressive B-cell non-Hodgkin's lymphoma (NHL)

EXCLUDING: Burkitt's lymphoma and precursor B lymphoblastic leukemia/lymphoma
INCLUDING: any non-Hodgkin's B cell malignancy such as chronic lymphocytic leukemia (CLL) and rare non-Hodgkin's B- cell subtypes such as hairy cell leukemia, Waldenström macroglobulinemia (WM), mantle cell leukemia (MCL), and transformed NHL histologies
Hodgkin's lymphoma (HL)
Life expectancy of 12 weeks or longer
Subject must have received ≥ 1 prior treatment regimen(s)
The subject must not be a candidate for potentially curative therapy including hematopoietic stem cell transplantation, except where one of the standard therapy regimen combinations may be used prior to transplantation per standard medical practice

Exclusion Criteria:

Has history of brain metastasis, spinal cord compression (unless treated, asymptomatic, and stable on most recent imaging and enrolling in expansion cohort), or lymphoma involving the central nervous system (CNS)
Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3 (≥ 2 during dose escalation)
Received allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or currently receiving immunosuppressive therapy following allogeneic transplant
Received autologous hematopoietic stem cell transplant within the last 3 months
Inadequate marrow reserve assessed by hematologic laboratory parameters
Inadequate renal or liver function
Known HIV infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or at risk for HBV reactivation
Intervention: Parsaclisib
Trial phase: Phase 1 | Phase 2
ATC code: L01EM05
SMILES: CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Participants self-administered parsaclisib 45 mg as oral tablets QD in 21-day treatment cycles.
Eligibility criteria:
Inclusion Criteria:

Aged 18 years or older, with lymphoid malignancies of B-cell origin including:

Indolent / aggressive B-cell non-Hodgkin's lymphoma (NHL)

EXCLUDING: Burkitt's lymphoma and precursor B lymphoblastic leukemia/lymphoma
INCLUDING: any non-Hodgkin's B cell malignancy such as chronic lymphocytic leukemia (CLL) and rare non-Hodgkin's B- cell subtypes such as hairy cell leukemia, Waldenström macroglobulinemia (WM), mantle cell leukemia (MCL), and transformed NHL histologies
Hodgkin's lymphoma (HL)
Life expectancy of 12 weeks or longer
Subject must have received ≥ 1 prior treatment regimen(s)
The subject must not be a candidate for potentially curative therapy including hematopoietic stem cell transplantation, except where one of the standard therapy regimen combinations may be used prior to transplantation per standard medical practice

Exclusion Criteria:

Has history of brain metastasis, spinal cord compression (unless treated, asymptomatic, and stable on most recent imaging and enrolling in expansion cohort), or lymphoma involving the central nervous system (CNS)
Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3 (≥ 2 during dose escalation)
Received allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or currently receiving immunosuppressive therapy following allogeneic transplant
Received autologous hematopoietic stem cell transplant within the last 3 months
Inadequate marrow reserve assessed by hematologic laboratory parameters
Inadequate renal or liver function
Known HIV infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or at risk for HBV reactivation
Intervention: Vancomycin
Trial phase: Phase 2 | Phase 3
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Vancomycin 1g is administered via forearm vein, given over a one-hour infusion, timed to finish approximately 30 minutes prior to tourniquet inflation.
Eligibility criteria:
Inclusion Criteria:

Revision total knee arthroplasty
Informed consent given

Exclusion Criteria:

Current treatment with IV Vancomycin within the preceding 7 days
Previous hypersensitivity to vancomycin
Significant cardiac or respiratory abnormality
Contraindications to using the intraosseous vascular access system (EZ-IO)
Sepsis
Intervention: Bimatoprost
Trial phase: Phase 4
ATC code: S01EE03
SMILES: CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 87
Group description: 0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of open-angle glaucoma or ocular hypertension
No use of Lumigan® in the past 3 months

Exclusion Criteria:

Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months
Intervention: Ledipasvir
Trial phase: Phase 3
ATC code: J05AP51
SMILES: COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 384
Group description: LDV/SOF (90/400 mg) FDC tablet administered once daily without regard to food for 12 weeks in treatment-experienced and treatment-naive participants in China, Korea, and Taiwan
Eligibility criteria:
Key Inclusion Criteria:

Willing and able to provide written informed consent
HCV RNA ≥ 10^4 IU/mL at screening
HCV treatment-naive, as defined as no prior exposure to any interferon (IFN) or other approved or experimental HCV-specific direct-acting antiviral agent; OR HCV treatment-experienced with medical records that include sufficient detail of prior IFN-based treatment to allow for categorization of prior response as either intolerant, non-responder, or experienced viral breakthrough or relapse.
Genotype 1 HCV at screening
HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy

Key Exclusion Criteria:

Pregnant or nursing female
Chronic liver disease of a non-HCV etiology
Current or prior history of any clinically-significant illness (other than HCV)
Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Intervention: Ticagrelor
Trial phase: Phase 1
ATC code: B01AC24
SMILES: CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 13
Group description: Healthy subjects (HS) with normal renal function (CrCL of ≥90 mL/min) received one oral 90 mg ticagrelor tablet
Eligibility criteria:
Inclusion Criteria:

Male or Female aged 18 to 80 years (inclusive).
Normal renal function (CrCl of ≥90 mL/min) or End Stage Renal Disease (ESRD) requiring hemodialysis.

Exclusion Criteria:

Any indication for oral anticoagulant or anti platelet treatment during study period. Must be off treatment for at least 3 weeks (low dose 81mg aspirin is allowed for hemodialysis subjects only).
Acute Coronary Syndrome (ACS) within past 12 months.
Contraindications to ticagrelor (ie: active pathological bleeding, severe hepatic impairment, history of hemorrhagic stroke, allergic to ticagrelor).
Platelet count <100000/μL, hemoglobin <9g/dL
Blood donation within 90 days of dosing
Risk for bradycardia
Investigational drug within 30 days or 6 half-lives, whichever is longer, before dosing
Concomitant therapy with CYP3A inhibitors/substrates with narrow therapeutic index,or strong CYP3A inducers 14 days before dosing until completion of the follow-up visit.
History of alcohol, drug, or substance abuse within the past year
Clinically significant laboratory abnormalities as judged by the investigator.
Increased bleeding risk including GI bleeding in past 30 days; history of intracranial, retroperitoneal, or spinal bleeding, recent major trauma within 30 days of dosing, Sustained uncontrolled hypertension, history of hemorrhagic disorders.
Pregnant or lactating females, or females of child-bearing potential (ie, those who are not chemically or surgically sterilised or who are not post-menopause) who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator throughout the duration of the study OR females who have a positive pregnancy test at Visit 1.
Intervention: TERIPARATIDE
Trial phase: Phase 2
ATC code: H05AA02
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: 10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneously between 8-9 p.m., daily.

Teriparatide: recombinant human parathyroid hormone (1-34) subcutaneously every day at 8-9 pm
Eligibility criteria:
Inclusion Criteria:

Clinical criteria:

No warmth or redness of foot.
Difference in temperature between two foot < 2 degree Centigrade.
If deformity present , patient able to walk without aid.
History of resolved active Charcot's neuroarthropathy of foot.

Radiological criteria: Plain X-ray foot (weight bearing lateral and oblique) showing at least 3 of the following features -

Foot deformity.
Joint subluxations/dislocations.
Smoothening /Rounding of bone fragments.
Subchondral sclerosis/erosions.
Callus formation.
Joint space collapse.

Exclusion Criteria:

Active inflammatory phase of Charcot's neuroarthropathy.
Active on inactive Charcot's neuroarthropathy.
Osteomyelitis of foot bones.
Peripheral vascular disease.
Osteoporosis (T score less than or equal to -2.5 at lumbar spine or hip).
Renal failure ( estimated Glomerular Filtration Rate < 60 ml/min).
Previous/present bone malignancy.
Previous malignancy with metastases to bone.
Received teriparatide earlier.
Hyperparathyroidism.
Paget's disease of bone.
Pregnant women.
Received bisphosphonates in previous 18 months.
Patients with ulcer on the involved foot.
Patients previously taking Pioglitazone. -
Intervention: Saxagliptin
Trial phase: Phase 4
ATC code: A10BD10 | A10BD21 | A10BD25 | A10BH03
SMILES: N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Saxagliptin 5mg once daily for 12 weeks
Eligibility criteria:
Inclusion Criteria

Adults aged 40-70 years.
Diagnosis of type 2 diabetes within the previous 8 years using criteria of the American Diabetes Association
Currently treated with no hypoglycemic agents other than a stable dose (>3 months) of metformin (≥1.0 to ≤2 grams daily).
HbA1C between 6 to 9% (both inclusive)
BMI 25 to 39.9 kg/m2 (both inclusive)

Exclusion Criteria:

Contraindications for moderate exercise
Implanted devices (e.g., pacemakers) that may interact with Tanita scale
Previous coronary or cerebrovascular event within 6 months of screening or active or clinically significant coronary and/or peripheral vascular disease.
Low hematocrit <28 Units
Pre-existing liver disease and/or ALT and AST >2.5X's UNL
Kidney disease (serum creatinine levels ≥1.5 mg/dL for men, ≥1.4 mg/dL for women,Creatinine Clearance ≤50 mL/min)
History of pancreatitis, or cancer (except basal cell carcinoma)
Statin use started (or dose change) in the last 3 months.
Use of oral or injectable anti-diabetic medication other than Metformin
Use of any form of consistent-long term steroid medication (oral, inhaled injected or nasal) within the last 3 months
Systolic BP> 140 mmHg and diastolic BP> 90 mmHg
Active wounds or recent surgery within 3 months.
Inflammatory disease, or current use of anti-inflammatory drugs
triglycerides >400 mg/dL
untreated hyper/hypothyroidism Additionally, patients who are active smokers, patients who are pregnant, nursing women, and post menopausal women who are on hormone replacement therapy will be excluded.

Patients on low dose oral contraceptives will be allowed to participate as these formulations contain lesser amount of estrogens.
Intervention: Phenylephrine
Trial phase: Phase 4
ATC code: C01CA06 | R01AA04 | R01AB01 | R01BA03 | R01BA53 | S01FB01 | S01FB51 | S01GA05 | S01GA55
SMILES: CNC[C@H](O)c1cccc(O)c1
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 13
Group description: Phenylephrine for maintaining blood pressure within 10 % of baseline

Phenylephrine
Eligibility criteria:
Inclusion Criteria:

English speaking
Age ≥18 yrs
Pre-eclampsia (mild, or severe)
Non-laboring women
CD under spinal anesthesia

Exclusion Criteria:

Height < 5'0"
Allergy to phenylephrine or ephedrine, or any other standardized medication
Severe Cardiac disease in pregnancy with marked functional limitations (NYHA Class III and IV)
Patients on Monoamine Oxidase Inhibitors or Tricyclic Antidepressants
History of recent amphetamine or cocaine use.
Subject enrollment in another study involving a study medication within 30 days of CD
Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection
Intervention: Ephedrine
Trial phase: Phase 4
ATC code: A08AA56 | C01CA26 | R01AA03 | R01AB05 | R01BA02 | R01BA52 | R03CA02 | S01FB02
SMILES: CN[C@@H](C)[C@@H](O)c1ccccc1
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 13
Group description: Ephedrine for maintaining blood pressure within 10 % of baseline

Ephedrine
Eligibility criteria:
Inclusion Criteria:

English speaking
Age ≥18 yrs
Pre-eclampsia (mild, or severe)
Non-laboring women
CD under spinal anesthesia

Exclusion Criteria:

Height < 5'0"
Allergy to phenylephrine or ephedrine, or any other standardized medication
Severe Cardiac disease in pregnancy with marked functional limitations (NYHA Class III and IV)
Patients on Monoamine Oxidase Inhibitors or Tricyclic Antidepressants
History of recent amphetamine or cocaine use.
Subject enrollment in another study involving a study medication within 30 days of CD
Any other physical or psychiatric condition which may impair their ability to cooperate with study data collection